Nasal Decongestant Final Rule Six-Month Stay Sought By P&G
This article was originally published in The Tan Sheet
Executive Summary
A six-month stay of the effective date of FDA's final rule switching the name of the OTC nasal decongestant ingredient l-desoxyephedrine to levmetamfetamine is requested by Procter & Gamble in a Sept. 7 petition.
You may also be interested in...
OTC nasal decongestant monograph amended to add levmetamfetamine.
OTC NASAL DECONGESTANT MONOGRAPH AMENDED TO ADD LEVMETAMFETAMINE, formerly known as l-desoxyephedrine, as a safe and effective OTC active ingredient, FDA announces in a final rule published in the July 30 Federal Register. L-desoxyephedrine was excluded from the August 1994 final monograph for nasal decongestant drug products because U.S. Pharmacopoeial standards did not exist for the ingredient. USP proposed a monograph for l-desoxyephedrine in the January/February 1997 Pharmacopeial Forum, which included the name change to levmetamfetamine. In affirming levmetamfetamine's GRAS/E (generally recognized as safe/effective) status, the final rule removes l-desoxyephedrine from the list of nonmonograph active ingredients.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands